Parallel Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Parallel Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-768	Closed	-$680	–	3551
2022 Q4	$680	Hold	768	–	–	﹤0.01%	2977
2022 Q3	$1K	Hold	768	–	–	﹤0.01%	3091
2022 Q2	$2K	Buy	768 +391	+104%	+$676	﹤0.01%	2677
2022 Q1	$1K	Buy	377 +300	+390%	+$936	﹤0.01%	2905
2021 Q4	$0	Hold	77	–	–	﹤0.01%	3394
2021 Q3	$1K	Hold	77	–	–	﹤0.01%	3012
2021 Q2	$1K	Hold	77	–	–	﹤0.01%	2889
2021 Q1	$1K	Buy	77 +2	+3%	+$21	﹤0.01%	2737
2020 Q4	$1K	Buy	+75	New	+$602	﹤0.01%	2524
2020 Q2	–	Sell	-200	Closed	–	–	2790
2020 Q1	$0	Sell	200 -300	-60%	-$864	﹤0.01%	2739
2019 Q4	$2K	Hold	500	–	–	﹤0.01%	2262
2019 Q3	$1K	Buy	+500	New	+$1.17K	﹤0.01%	2354
2019 Q2	–	Sell	-2,000	Closed	-$10K	–	2477
2019 Q1	$10K	Buy	+2,000	New	+$5.25K	﹤0.01%	1547

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Parallel Advisors's SRNE Position: Q1 2023 in Review

Parallel Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 768 shares — an estimated $680 sold.

Parallel Advisors first reported a position in SRNE in Q1 2019 and held it in 13 quarters. The position peaked at $10K in Q1 2019. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

Parallel Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Parallel Advisors sold 768 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $680.
Parallel Advisors first reported a position in Sorrento Therapeutics, Inc. in Q1 2019 and held it in 13 quarters.
Parallel Advisors's Sorrento Therapeutics, Inc. position peaked at $10K in Q1 2019.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Parallel Advisors's 13F filing for Q1 2023, filed 25 Apr 2023.